Research programme: C16 conjugated small interfering RNA-based therapeutics - Alnylam Pharmaceuticals
Alternative Names: Research programme: C16-siRNA therapeutics - Alnylam PharmaceuticalsLatest Information Update: 10 Jun 2022
At a glance
- Originator Alnylam Pharmaceuticals
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders; Eye disorders; Lung disorders
Most Recent Events
- 08 Jun 2022 Preclinical trials in Lung disorders in USA (Intranasal), before June 2022
- 02 Jun 2022 Preclinical trials in Eye disorders in USA (Intravitreous), before June 2022
- 02 Jun 2022 Pharmacodynamics data from the preclinical studies in CNS disorders, Eye disorders and Lung disorders released by Alnylam Pharmaceuticals